TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04117607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 5% Dextrose Injection, USP, a sterile, nonpyrogenic solution of dextrose in water for injection. The solution has the osmolarity of 252 mOsmol/L, which is slightly hypotonic. This solution contains no bacteriostat, antimicrobial agent or added buffer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 5% Dextrose Injection, USP, a sterile, nonpyrogenic solution of dextrose in water for injection. The solution has the osmolarity of 252 mOsmol/L, which is slightly hypotonic. This solution contains no bacteriostat, antimicrobial agent or added buffer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 5% Dextrose Injection, USP, a sterile, nonpyrogenic solution of dextrose in water for injection. The solution has the osmolarity of 252 mOsmol/L, which is slightly hypotonic. This solution contains no bacteriostat, antimicrobial agent or added buffer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 5% Dextrose Injection, USP, a sterile, nonpyrogenic solution of dextrose in water for injection. The solution has the osmolarity of 252 mOsmol/L, which is slightly hypotonic. This solution contains no bacteriostat, antimicrobial agent or added buffer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 5% Dextrose Injection, USP, a sterile, nonpyrogenic solution of dextrose in water for injection. The solution has the osmolarity of 252 mOsmol/L, which is slightly hypotonic. This solution contains no bacteriostat, antimicrobial agent or added buffer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 5% Dextrose Injection, USP, a sterile, nonpyrogenic solution of dextrose in water for injection. The solution has the osmolarity of 252 mOsmol/L, which is slightly hypotonic. This solution contains no bacteriostat, antimicrobial agent or added buffer.
Study: NCT01630018

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Belotecan
Description: 0.5mg/m2 IV days 1,2,3,4,5 of each 21day cycle until 6cycle or disease progression
Study: NCT00223665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide
Description: Flutamide dosed at 250mg orally three times a day for 14 days prior to the initiation of Leuprolide Acetate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Leuprolide Acetate dosed at 7.5mg intramuscular (IM) injections once per month for a total of 9 months.
Study: NCT01488552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 weekly on days 1,8, and 15 in a 28 day cycle. Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: 125 mg/m2 on days 1,8, and 15 of a 28 day cycle Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: The combination below will be given on days 1 and 15 of a 28 day cycle; 5-Fluorouracil 2400 mg/m2 with a 46-hour continuous IV infusion; Leucovorin 400 mg/m2 over a 2 hour IV infusion;~Oxaliplatin 85 mg/m2 as a 2 hour IV infusion; Irinotecan 180 mg/m2 over a 90 minute IV infusion Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
Study: NCT00600496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: twice daily oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: twice daily oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: twice daily oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: twice daily oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: daily oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: intravenous infusion
Study: NCT01488552

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry (IHC) Analysis
Description: Immunohistochemistry (IHC) Analysis will be performed on a fresh tissue biopsy of the tumor after chemotherapy has been administered. A targeted-based regimen will be determined from the results of the IHC analysis for the next therapy given to the patient in the maintenance phase of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500 mg daily as a 24 hour extended release tablet will also be given as part of the maintenance phase of this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRI
Description: 5-FU IV infusion, 2400 mg/m2 46h continuous infusion (no bolus 5-FU) treatments per month equaling 1 cycle Leucovorin 400 mg/m2 dl (over a 2 hour IV infusion) Irinotecan 180 mg/m2 dl (over a 90 minute IV infusion) Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
Study: NCT04408651

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LIIT.CI ACT
Description: 4-week online self-management intervention based on Acceptance and Commitment Therapy and adapted to people with chronic medical conditions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LIIT.CI CFT
Description: 4-week online self-management intervention based on Compassion-Focused Therapy and adapted to people with chronic medical conditions
Study: NCT00624000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV tpa (Alteplase) vs IA tpa (Alteplase)
Description: Alteplase was administered Either IA or IV x 1
Study: NCT00624000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV tpa (Alteplase) vs IA tpa (Alteplase)
Description: Alteplase was administered Either IA or IV x 1
Study: NCT03295240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR-I (bendamustine, rituximab, ibrutinib)
Description: The BR-I (bendamustine, rituximab, ibrutinib) regimen will be administered for six 28-day cycles: bendamustine (90 mg/m2; (or 70mg/m2 for dose level -1); day 1 and 2 ), rituximab (375 mg/m2; day 1), and ibrutinib one pill or four 140mg capsules (560 mg oral daily; day 1-28).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEN (Venetoclax)
Description: The initial cycle 1 VEN (Venetoclax) dose ramp-up will be: 20 mg daily for 1 week, 50 mg daily for week 2, 100 mg daily for week 3, and 200 mg daily for week 4. Thereafter, VEN will be administered at a fixed dose level of 400 mg daily for varying durations of each 28-day cycle. Now also include a -2 dose level which has the reduced 3-day duration of Ventoclax 400 mg daily.
Study: NCT04396600

Intervention type: BEHAVIORAL
Intervention: MinnRAP Peer Support Program
Description: The behavioral intervention consists of 1) pairing healthcare workers into Battle Buddies who maintain daily dialogue to detect stress and anxiety and 2) assigning a mental health consultant to each department to facilitate Battle Buddies and provide both small group sessions and individual psychological triage/referrals.

Intervention type: BEHAVIORAL
Intervention: MinnRAP Peer Support Program
Description: The behavioral intervention consists of 1) pairing healthcare workers into Battle Buddies who maintain daily dialogue to detect stress and anxiety and 2) assigning a mental health consultant to each department to facilitate Battle Buddies and provide both small group sessions and individual psychological triage/referrals.
Study: NCT02654158

Intervention type: DRUG
Intervention: Low-dose of Fuganlin Oral Liquid
Description: less than 1 years old: 5mL each time and three times a day~1\~3 years old: 10mL each time and three times a day~4\~6 years old: 10mL each time and four times a day~7\~12 years old: 10mL each time and five times a day

Intervention type: DRUG
Intervention: High-dose of Fuganlin Oral Liquid
Description: less than 1 years old: 10mL each time and three times a day~1\~3 years old: 20mL each time and three times a day~4\~6 years old: 20mL each time and four times a day~7\~12 years old: 20mL each time and five times a day
Study: NCT04387461

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CG0070
Description: Engineered Oncolytic Adenovirus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection
Description: Immune checkpoint inhibitor, Monoclonal antibody

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: n-dodecyl-B-D-maltoside
Description: Transduction-enhancing agent.
Study: NCT00701792

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: liver transplantation
Description: liver transplantation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard care for liver disease
Description: standard care for liver disease included therapy for ascitis (spironolactone, furosemide), portal hypertension (oesophageal varices ; propranolol), encephalopathy (lactulose), and bacterial infections whatever their localization (prophylaxis of spontaneous peritonitis with norfloxacin). All medical or instrumental procedures were allowed. Patients undergoing iterative paracentesis, variceal band ligation or sclerotherapy, peritoneojugular shunt (LeVeen), transjugular intrahepatic portosystemic shunt (TIPS) or surgical portocaval anastomosis were considered as receiving standard medical therapy.
Study: NCT04086745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TNF Inhibitor
Description: Administered SC
Study: NCT04353492

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Subjects will receive ofatumumab injections in an autoinjector (AI) for subcutaneous administration containing 20 mg ofatumumab (50 mg/ml, 0.4 ml content)
Study: NCT00971490

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acu-TENS (Transcutaneous electrical nerve stimulation)
Description: Transcutaneous electrical nerve stimulation applied onto acupuncture point

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Acu-TENS (Transcutaneous electrical nerve stimulation)
Description: Similar to Group 1 but without electrical stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Acu-TENS (Transcutaneous electrical nerve stimulation)
Description: Similar to Group 1 but applied onto non acupuncture point
Study: NCT03461458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Adipose-Derived Mesenchymal Stromal Cells
Description: Human, autologous, culture expanded, adipose-derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Immune Progenitor and Cell Therapeutics Laboratory using current good manufacturing practices (cGMPs).
Study: NCT03153527

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: The control intervention (standard treatment) consists of prednisone treatment in decreasing doses, starting with 7.5 mg q.d. and reducing the dose every 7 days, such that prednisone treatment is stopped after a total of 4 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Arm
Description: The experimental intervention consists of stopping glucocorticoid treatment abruptly and administering matching placebo over 4 weeks.
Study: NCT00972478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study: NCT05504057

Intervention type: DRUG
Intervention: Antihistamine
Description: Observation of the rate of COVID19 infection, the rate of hospitalization and the rate of survival among patients previously treated with

Intervention type: DRUG
Intervention: Amantadine
Description: Observation of the rate of COVID19 infection, the rate of hospitalization and the rate of survival among patients previously treated with amantadine
Study: NCT02235623

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Single-stage Fowler-Stephens orchidopexy (FSO)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Two-stage Fowler-Stephens orchidopexy (FSO)
Study: NCT02942355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: Anastrozole by mouth daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: Anastrozole by mouth daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib by mouth daily days 1-21 every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib by mouth daily days 1-21 every 28 days
Study: NCT03659734

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing and Guided Opioid Tapering Support
Description: Following surgery, participants will undergo motivational interviewing with a trained member of the study staff. These calls will occur weekly for 6 weeks with a follow-up call at 10 weeks or until the participant completes the protocol.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Usual Care
Description: Following surgery, participants will receive phone calls from a trained member of the study staff to discuss various aspects of surgical recovery and medication use. These calls will occur weekly for 6 weeks with a follow-up call at 10 weeks or until the participant completes the protocol.
Study: NCT04263051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCPVax + Nivolumab
Description: UCPVax will be administrated at day 1 of week 1 ; 2 ; 3 ; 5 ; 6 ; 7 and then week 13 and every 2 months until months 12.~Nivolumab will be administrated at the dose of 480 mg at day 1 and then every 4 weeks until disease progression or unacceptable toxicity according to label.~At the end of COMBO phase, nivolumab will be continued every 4 weeks for maximum 24 months from the first administration, until disease progression or unacceptable toxicity according to standard of care.

Intervention type: DRUG
Group type: OTHER
Intervention: standard chemotherapy
Description: Second line chemotherapy at the choice of the investigator
Study: NCT01135043

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education by brochure
Description: educated with the brochure that contains figure of lung/upper respiratory tract and methods of collecting sputum.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: patients with control group are educated about methods of collecting sputum by a physician, only in verbal explanation without brochure
Study: NCT03367299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy + Blinatumomab
Description: Chemotherapy cycles are administered at 21-28 days intervals and each blinatumomab course is 28-day long.
Study: NCT03830762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanamem
Description: Oral Xanamem capsules 20mg or 30mg, administered PO once daily. Xanamem is formulated in green and cream coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains active pharmaceutical ingredient of UE2343.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching placebo which is identical in appearance to the test product (20mg, 30mg Xanamem™ QD) except that it contains no active ingredient.
Study: NCT00217737

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study: NCT02772536

Intervention type: OTHER
Group type: OTHER
Intervention: Visual Stimulus Condition Set
Description: In this single arm study, all participants are subject to a set of three visual stimulus conditions.~Low ambient light for 10 mins: Self selected tinted light (20 Mins); White light (20 mins).~VAS/CGI scores for each stimulus condition in the above set are reported at five minute intervals.
Study: NCT01669395

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early homebased rehabilitation after hospital admission
Description: Training begins 3-5 days after discharge from hospital, performed by an occupational therapist and a physiotherapist from Gentofte Hospital in the first two weeks. From week three to six the training will be carried out by an occupational therapist and a physiotherapist from the local municipality (Gentofte municipality and Lyngby Taarbæk municipality). Training will take place at home twice a week for 6 weeks, each session lasting 45 minutes. The intervention is individualized and focuses on functional physical and compensatory training to help the patient to manage everyday life at home. A training program will be provided and the patient will be instructed to do the exercises every day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: After discharge from the hospital the patients are offered the usual symptom-oriented and preventive medical care and psychosocial support
Study: NCT04287881

Intervention type: GENETIC
Group type: OTHER
Intervention: Methylenetetrahydrofolate reductase (MTHFR) deficiency
Description: To investigate the incidence of MTHFR deficiency in patients with adult-onset epileptic seizures and diagnosed ischemic stroke
Study: NCT02594462

Intervention type: DRUG
Group type: OTHER
Intervention: etonogestrel-releasing implant contraceptive
Description: The etonogestrel implant will be inserted until the fifth day of the menstrual cycle . Anthropometric measurements will be performed , blood pressure measurement , application of pain questionnaire for the last three months, and collection of fasting blood in our clinic . After these measures , the ENG implant will be applied per researcher trained for such a procedure , following the recommendations outlined by the manufacturer. Women are instructed to return after 3, 6, 9, 12 months, fasting 8h , when they will be measured anthropometric measurements , blood collection, and delivery of pain questionnaires and standard of menstrual bleeding.
Study: NCT03317613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qutenza
Description: Patients suffering from neuropathic pain will receive patch of capsaicin (qutenza) on the painful zones. Three months after the first application, patients will be allowed to receive another patch if necessary. They will be able to receive one every three months. They will be followed in the study during one year after the first patch application.
Study: NCT00001337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPOCH
Description: Combination chemotherapy given with Rituximab (EPOCH-R) IV every 3 weeks for 6 cycles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab given on Day 1 of combination chemotherapy (EPOCH-R) every 3 weeks for 6 cycles.
Study: NCT00156949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alfa DT
Description: Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL
Study: NCT04236765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TB infection-screening benefiting group
Description: The children who participate in the study will be recruited during a programmed visit to a traveler health clinic or a primary care center. During the first visit the parents or legal guardian will be interviewed, a questionnaire will be completed with sociodemographic, epidemiologic and clinical data and a tuberculin skin test (TST) will be performed and read at 48-72 hours. At 8-12 weeks after returning from the travel abroad the child will have a new visit. A new interview will be carried out with the parents or legal guardian and a questionnaire will be completed with epidemiological and clinical data. The child will undergo a new TST and QFT-Plus test.
Study: NCT04648475

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 and CD22 targeted CAR-T cells
Description: A single infusion of CD19 and CD22 CAR-T cells will be administered intravenously
Study: NCT02328781

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-eluting stent
Study: NCT02879279

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amadeo, Pablo, Diego and Motore.
Description: In the robotic rehabilitation group, patients will be treated with the following systems: Amadeo, Pablo and Diego (Tyromotion GmbH, Austria), and Motore (Humanware, Italy). A ratio of one therapist to every 3 or 4 patients will be used, depending on the patient's severity. The rehabilitation treatment will be performed daily for 45 minutes, for 5 days per week, for 6 weeks. A total of 30 sessions will be performed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: In the conventional rehabilitation group, patients will undergo a conventional treatment with a ratio of one therapist to one patient. The rehabilitation treatment will be performed daily for 45 minutes, for 5 days per week, for 6 weeks. A total of 30 sessions will be performed.